Navigation Links
Cellular force that drives allergy and asthma can be blocked by interferon
Date:6/16/2014

DALLAS June 16, 2014 A mechanism that could underlie the development of cells that drive asthma and allergies has been uncovered by immunology researchers at UTSouthwestern Medical Center.

Asthma and allergies are both driven by an inappropriate activation of the immune system, primarily a subtype of white blood cells known as T helper 2 cells, or Th2 cells. These cells are normally responsible for defense against parasites, but are also the main culprits behind the symptoms of asthma and allergies.

Dr. David Farrar, Associate Professor of Immunology and Molecular Biology at UTSouthwestern, and his team found that the antiviral molecules known as type I interferons (IFNs) block the development of these allergy- and asthma-driving Th2 cells.

"The fact that interferon could stop the activation of these harmful cells was of particular interest because interferons are already approved by the Food and Drug Administration for the treatment of other diseases, such as multiple sclerosis and hepatitis," said Dr. Farrar, who holds the J. Wayne Streilein, M.D. Professorship in Immunology.

The work, published in the Journal of Immunology, could eventually give rise to new therapies.

To demonstrate the prevalence of asthma, in the United States about 13 percent of adults nearly 30 million people have received a diagnosis of asthma. This frequency compares to 11 percent who have been diagnosed with heart disease and 8 percent who have had any form of cancer, according to the Centers for Disease Control and Prevention. Asthma is reported more often among women than men, among Caucasians, and in families with limited economic resources. Allergies, too, are prevalent, with more than 17.5 million people suffering from hay fever in the U.S.

The development of Th2 cells is stimulated by a particular immune molecule that triggers the production of a protein called GATA3. Frequently referred to as the master regulator of Th2 cell development, GATA3 turns on the genes that distinguish Th2 cells from other cell types, including other T cells.

Dr. Farrar's group found that type I IFNs block this process by targeting a part of the GATA3 gene known as exon 1a and turning it off, thereby inhibiting the production of the GATA3 protein and, consequently, the development of Th2 cells.

"Targeting this pathway may lead to permanent tolerance of these cells to allergens," said Dr. Farrar. "We are currently pursuing studies that may lead to clinical trials that will determine whether interferon can be used to treat allergic asthma patients."

Dr. Farrar's lab studies how a collective group of proteins called cytokines regulate immune responses. Type 1 interferon, the first immune cytokine discovered, is one of the very first lines of defense against viruses. The protein was initially identified based on its ability to inhibit influenza virus. Since then, scientists have discovered that almost any cell in the body can secrete interferon if it becomes infected with certain viruses, and that most cells can respond to interferon.


'/>"/>
Contact: Russell Rian
russell.rian@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Cellular pathway linked to diabetes, heart disease
2. Why omega-3 oils help at the cellular level
3. Discovery explains how cellular pathways converge to regulate food intake and body weight
4. New technique reveals cross-talk between 2 essential cellular processes
5. LA BioMed investigator, Dr. Yutaka Niihara, developing novel cellular therapy
6. Molecular switch identified that controls key cellular process
7. MedScope Announces Changes to the Medical Alarm Industry, Bringing it into the Cellular Age
8. The new age of proteomics: An integrative vision of the cellular world
9. Research explores road signs on the intracellular highway
10. Extracellular vesicles may open new opportunities for brain cancer diagnosis and treatment
11. Study: HIV Infection Does Not Adversely Affect Outcomes of Liver Transplantation for Hepatocellular Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cellular force that drives allergy and asthma can be blocked by interferon
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology: